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In vivoAt present no scientific rationale exists for selecting a particular enabling strategy to formulate a poorly water-
soluble drug, although this is crucial as it will influence the in vivo performance of the resulting formulation.
This study provides an insight into this complicated decision making process for a poorly soluble human immu-
nodeficiency virus (HIV) protease inhibitor based upon in vivo test results. A formulation strategy based on the
molecular dispersion of this active pharmaceutical ingredient (API) into a biphasic matrix consisting of water-
insoluble poly(lactic-co-glycolic acid) (PLGA) and water-soluble polyvinylpyrrolidone (PVP) was evaluated.
The long-term in vivo performance of this strategy was compared to that of other solubility enhancing ap-
proaches by evaluating exposure of the API in male Beagle dogs. Solid dispersions, based on a PLGA/PVP matrix,
were compared to solid dispersions in a pure PLGA matrix. Additionally these solid dispersion strategies were
compared to the strategy of particle size reduction bymeans of an API microsuspension. The in vivo performance
of the various formulations over a period of 28 days after intramuscular injection was evaluated by the observed
initial burst release, plasma concentration-time profiles, time at which maximum plasma levels were reached
and the estimated bioavailability. Compared to the other formulation strategies assessed, it was concluded that
the addition of PVP in a PLGA matrix resulted in vivo in a more sustained release as well as a higher amount of
drug released from the polymeric matrix. This was explained based on the structure of these binary PLGA/PVP
matrices where the pore network originating from rapidly dissolving PVP plays a key role. Moreover, the results
suggest that the API release from this type of formulation could be delayed by increasing the amount of PLGA in
the formulation.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Contemporary drug pipelines contain an increasing number of poor-
ly water-soluble candidates. To overcome this problem, solubility en-
hancing technologies commonly focus on impacting aspects of the
modified Noyes–Whitney relationship by increasing dissolution rate
or drug solubility. Examples of these approaches for solubility enhance-
ment are the solid dispersion of a poorly soluble active pharmaceutical
ingredient (API) in an inert matrix, particle size reduction, the use of
co-crystals, inclusion complexation with cyclodextrins and lipid based
systems [1–10]. At present no scientific rationale exists for selecting a
particular enabling strategy, although this is important as it will influ-
ence the in vivo performance of the resulting formulation. The present
study provides an insight into this complicated decisionmaking procession, KU Leuven, Department of
asthuisberg ON2, Herestraat 49
be (G. Van den Mooter).for a poorly soluble human immunodeficiency virus (HIV) protease in-
hibitor (PI) based upon in vivo test results.
This poorly soluble model compound requires formulation into an
effective long-acting medicine for HIV pre-exposure prophylaxis thera-
py. The use of long-acting injectables has been suggested to prevent the
transmission of HIV via pre-exposure prophylaxis and could for exam-
ple be effective in preventing mother-to-child transmission, transmis-
sion within serodiscordant couples as well as protecting intravenous
drug users [11]. Long-acting formulations are desirable as dosing fre-
quencywill be significantly reduced, favouring therapy compliancy. Ad-
ditionally, they allow sustained release of appropriate amounts of drug
resulting in relatively low but constant drug plasma concentrations
which is sought-after for this HIV pre-exposure prophylaxis approach.
In view of this, we previously reported on the development of spray-
dried polymeric microspheres for intramuscular injection for the long-
term pre-exposure prophylaxis of infection with HIV [12,13]. The for-
mulation strategy was based on the solid dispersion of a poorly soluble
API in a polymeric matrix consisting of water-soluble polyvinylpyrroli-
done (PVP) and water-insoluble poly(lactic-co-glycolic acid) (PLGA).
2 J. Meeus et al. / Journal of Controlled Release 199 (2015) 1–9This combination of materials aimed to secure both solubility enhance-
ment by molecular dispersion of the drug (in PVP) and long-term re-
lease (by PLGA) (strategy 1).
In the present study the in vivobehaviour of the formulation strategy
of a solid dispersion in a binary polymeric matrix combining a water-
insoluble polymer (PLGA) with a water-soluble polymer (PVP) (strate-
gy 1)was evaluated inmale Beagle dogs. The in vivo performance of this
formulation strategy was compared to the in vivo performance of two
other strategies. The second strategy was based on formulating the
poorly soluble API as a solid dispersion in a polymeric matrix made up
of pure PLGA. PLGA is already well established as a formulation matrix
for long-term release as exemplified by commercial products like
Trelstar® Depot (Debio RP) [14] and Risperdal®Consta® (Janssen)
[15]. Hence, formulation strategy 1 and 2 differed at the level of the
polymeric matrix and can be divided in two groups, namely formula-
tions based upon a PLGA/PVPmatrix (strategy 1) compared to formula-
tions made up of a pure PLGA matrix (strategy 2). Consequently the
potential benefit of the inclusion of PVP was assessed.
Additionally, these solid dispersion strategies were compared to the
strategy of particle size reduction by means of an API microsuspension
(strategy 3). Particle size reduction is a commonly applied strategy to
increase dissolution rate of poorly soluble compounds. This is exempli-
fied by various publications on micro and nanoparticles aiming to im-
prove the dissolution performance of a poorly soluble compound [1,2,
16]. This strategy has already resulted in the production of successfully
marketed formulations such as Invega® Sustenna® [17] (Janssen) and
Triglide® (Sciele Pharma Inc) [18].
Six intramuscularly (IM) injectable sustained release formulations
for HIV prophylaxis with a poorly soluble PI were previously developed
and physicochemically characterized [19]. These six formulations repre-
sent the three different solubility enhancing strategies selected. They
differed in composition and manufacturing method and consequently
in structural and physicochemical characteristics. In the current study
the in vivo performance of these six formulations is evaluated in male
Beagle dogs. The structural and physicochemical properties of these for-
mulations were taken into consideration to explain the observed plas-
ma concentration-time profiles.2. Experimental section
2.1. Materials
Poly(lactic-co-glycolic acid) (PLGA) (lactide:glycolide molar ratio of
75:25, inherent viscosity of 0.2 dL/g) was purchased from PURAC Bio-
materials (Gorinchem, The Netherlands). Polyvinylpyrrolidone K30
(PVP K30) (MW 44–54 kDa) and polyvinylpyrrolidone K12 PF (PVP
K12) (MW 2–3 kDa) were kindly donated by BASF (Ludwigshafen,
Germany). The API was a poorly soluble HIV protease inhibitor (PI) pro-
vided by Janssen (Beerse, Belgium). The structural formula is shown in
Fig. 1. Polyvinyl alcohol (PVA) (80% hydrolyzed, MW 9–10 kDa) wasFig. 1. Structural formula of the API, a poorly soluble HIV protease inhibitor.obtained from Sigma-Aldrich (Diegem, Belgium). Tocopheryl polyethyl-
ene glycol 1000 succinate (TPGS) was supplied by Eastman Chemical
Company (Anglesy, UK). Dichloromethane (DCM) was provided by
Fisher Scientific (Leicestershire, United Kingdom).
2.2. Methods
Table 1 provides an overview of the composition andmanufacturing
method of various formulations tested. From here on the formulations
will be indicated by their code F1–F6 as shown in Table 1.
2.3. Formulation manufacturing
2.3.1. Spray drying
F1–F4 were spray dried with a Micro Spray lab scale spray dryer
(ProCepT, Zelzate, Belgium) starting from a 5% feed solution in DCM.
The inlet temperature was set to 115 °C and the feed rate was 6 ml/min.
The co-current drying air had a flow rate of 0.2m3/min and the atomizing
air was supplied with a pressure of 1.25 bar.
2.3.2. Oil-in-water emulsion method
Microspheres of API/PLGAwere produced using an oil-in-water (o/w)
emulsionmethod (F5). 900.0mg of API was dissolved in 30.0ml DCM to-
getherwith 2100.0mgPLGA. This solutionwas emulsified in 150.0ml of a
1.25% PVA solution for 5 min using an Ultra Turrax® homogenizer (IKA,
Staufen, Germany) at 20,000 rpm to form the o/w emulsion. During ho-
mogenization the sample was placed in an ice bath to minimize heating.
After addition of 150.0 ml of distilled water, the suspension was stirred
overnight with a magnetic stirrer to allow the organic solvent to evapo-
rate as the microparticles hardened. The resulting microparticles were
harvested and washed three times with deionized water. As a last step
the microparticles were freeze dried and consequently stored in a desic-
cator at room temperature.
2.3.3. Media milling of the microsuspension
The API microsuspension (F6) was prepared using a roller mill
(Peira, Turnhout, Belgium) and glass vials of the appropriate size filled
with zirconium oxide grinding beads with a diameter of 1.0 mm (Tosoh
Corporation, Tokyo, Japan). All samples were ground for 24 h. Subse-
quently these beads were replaced by beads of ø 0.5 mm. After 48 h ø
0.3 mm beads were used for the next 16 days. Suspensions consisted of
10% of drug in phosphate buffer of pH 7 containing 3.75% of TPGS.
2.4. In vivo performance
All in vivo experiments were performed in accordance with Belgian
laws andwere approved by the Local Ethics Committee on animal exper-
iments (Janssen (Beerse, Belgium), protocol 2013-512-PKADME_Tox).
2.4.1. Intravenous drug administration
An intravenous (IV) infusion study was performed to determine the
area under the curve (AUC) of the plasma concentration-time profile for
IV dosing as well as the plasma half-life (t1/2) of the API. For this study
three male Beagle dogs were fasted approximately 16 h before dosingTable 1
Overview of formulation composition and manufacturing method.
Formulation Composition (w%) Manufacturing method
Formulation 1 (F1) API/PLGA/PVP K30 30/25/45 Spray drying
Formulation 2 (F2) API/PLGA/PVP K30 30/45/25 Spray drying
Formulation 3 (F3) API/PLGA/PVP K12 30/45/25 Spray drying
Formulation 4 (F4) API/PLGA 30/70 Spray drying
Formulation 5 (F5) API/PLGA 30/70 Emulsion method
Formulation 6 (F6) API microsuspension Media milling
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formulation was prepared in a mixture of polyethylene glycol (PEG)
and water (PEG/water 70/30 v%) at a final analyzed concentration of
0.923 mg/ml. The test subjects were infused in a cephalic vein at a
dose of 1ml/kg for 1 h at an infusion rate of 1ml/h/kg. Hence the obtain-
ed final dose was 0.923mg/kg. Blood samples were collected from a sa-
phenous vein 15min, 30min and1 h after the start of the infusion and 2,
7 and 20min and 1, 2, 3, 4, 5 and 6 h after the end of the infusion. Imme-
diately after collection, the blood sampleswere placed onmelting ice till
centrifugation. Within 1 h after blood collection, blood samples were
centrifuged at 1900 g for 10 min. The plasma was separated and stored
at -20 °C till bioanalysis.
2.4.2. Intramuscular drug administration
The six formulations (F1–F6) were intramuscularly injected, each in
four male Beagle dogs. Prior to IM drug administration the test subjects
were fasted approximately 16 h and food was returned approximately
4 h post dosing. Before administration, the microspheres of F1–F5
were suspended in 3.75% TPGS containing phosphate buffer of pH 7.
For all formulations the administered drug dose was 23 mg/kg. Blood
samples were collected 0.5, 1, 2, 4, 6, 24, 55, 79, 223, 343, 511 and 679 h
post dosing from a saphenous vein. Immediately after collection, the
blood samples were placed on melting ice till centrifugation. Within 1 h
after blood collection, blood samples were centrifuged at 1900 g for
10 min. The plasma was separated and stored at−20 °C till bioanalysis.
2.4.3. Bioanalysis
Plasma levels of the API were determined using a qualified research
liquid chromatography–mass spectrometry/mass spectrometry (LC–MS/
MS)method. After protein precipitation (with acetonitrile) plasma samples
werequantifiedona reversedphaseultra-highperformance liquid chroma-
tography (UHPLC) column (Acquity BEH C18 1.7 μm, 50 × 2.1mm;Waters,
Milford, USA). Mobile phases consisted of 0.1% formic acid (solvent
A) and acetonitrile (solvent B). Starting conditions were 60% solvent A
and 40% solvent B followed by a linear gradient to 2% solvent A and
98% solvent B over 1.0 min followed by an isocratic hold at a flow rate
of 0.6 ml/min.
LC–MS/MS analysis was carried out on an API-4000MS/MS (Applied
Biosystems, Toronto, Canada), which was coupled to an UHPLC-system
(Nexera; Shimadzu, Kyoto, Japan). The MS/MS, operated in the positive
ion mode using the TurboIonSpray™-interface (electrospray ioniza-
tion), was optimized for the quantification of the compound. Multiple
reaction monitoring (MRM) transition was as follows: 575.0 N 419.2.
Samples were quantified against calibration curves prepared to cover
the concentration range of the study samples. The curveswere prepared
in the samematrix as the study samples. For each analytical batch, inde-
pendent quality control (QC) samples, prepared in the same matrix as
the samples, were analyzed together with the study samples and cali-
bration curve. The limit of quantification in canine plasma was at least
2 ng/ml. The accuracy (intra batch accuracy from independent QC sam-
ples) was between 85% and 115% of the nominal value over the entire
range for plasma samples.
2.4.4. Pharmacokinetic data analysis
Based on the plasma concentration-time profiles obtained by the IV
infusion study the half-life (t1/2) of the API was determined via Eq. (1).
t1=2 ¼
0:693
terminal slope 2:303 ð1Þ
The terminal slope was obtained by linear regression of the loga-
rithm (log10) of the plasma concentrations 2, 3, 4, 5 and 6 h after the
end of the infusion.
The AUC for both the intravenously and the intramuscularly dosed
API (AUCIV and AUCIM respectively) was calculated based on the plasma
concentration-time profiles using the linear-up log-down trapezoidalmethod. After the last time point (h(final)) the plasma concentration-
time profile was extrapolated to infinity in order to determine AUC0–∞.
Eq. (2) was used to estimate AUC h(final)–∞.
AUC h finalð Þ−∞ ¼
plasma concentration h finalð Þ
terminal slope
ð2Þ
The terminal slope was obtained by linear regression of the plasma
concentrations for the three last time points at which detectable API
plasma levels observed.
For each intramuscularly administered formulation, the measured
plasma exposure was used to calculate the bioavailability (F) (0–∞) by
Eq. (3).
F ¼ 100  doseIV  AUCIM; 0−∞
doseIM  AUCIV; 0−∞
ð3Þ
The intravenously administered dose (doseIV) was 0.92 mg/kg and
the intramuscularly administered dose (doseIM) was 23 mg/kg.
The initial burst release of the six formulations was determined
based on the observedplasma concentration till 4 h post administration.
The percentage of drug released within this timeframe was calculated
by Eq. (4).
Initial burst ¼ 100  AUCIM; 0−4h
AUCIM; 0−∞
ð4Þ
In this equation AUCIM,0–4h and AUCIM, 0–∞ represent the calculated
AUCs based upon the plasma concentration-time profile till 4 h post ad-
ministration and extrapolated to infinity respectively.
2.5. Statistical analysis
Statistical differences between the observed time after administra-
tion when maximum plasma concentrations were reached (tmax,obs)
for each of the formulations were evaluated via one-way ANOVA as
well as the initial burst release (4 h post administration) and bioavail-
ability. A Bonferroni post-hoc test was performed at an α level of 0.05.
(GraphPad Prism 5 for Windows; GraphPad Software Inc., San Diego,
USA).
2.6. Mimicking suspension and injection
To investigate the effect of the suspension of the powders of F1–F5 in
anaqueousmediumand subsequent IM injection this processwasmim-
icked in vitro. F1 was selected as a representative for the PLGA/PVP-
based formulations (F1–F3) whereas F4 was chosen as an example for
the PLGA-based formulations (F4–F5). Powder of both samples was
suspended in the same suspension medium and concentration as used
for IM injection in the canine test subjects (3.75% TPGS containing phos-
phate buffer of pH 7, 100 mg API/ml). Injection was mimicked by
injecting the suspended powders via a 20 G needle into a glass petri
dish. The resulting sample was dried in a vacuum oven for one week
at 25° and subsequently stored in a desiccator at room temperature.
2.7. Scanning electron microscopy
Scanning electron microscopy (SEM) was used to gain insight into
the morphology of the samples obtained by mimicking suspension
and injection for F1 and F4. Samples prepared by fixing an amount of
powder on an aluminium stub using double-sided carbon tape. The
samples were coated with a gold–palladium mixture by sputtering for
45 s at 20 mA. Field emission gun scanning electron micrographs
(FEG-SEM) were taken by using a Philips XL30 ESEM-FEG instrument
(Philips, Eindhoven, The Netherlands) at an acceleration voltage of
10 kV.
Fig. 3. Plasma concentration-time profiles up to five hours after IM administration of the
six formulations F1–F6 (mean ± SD, n = 4).
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3.1. Intravenous infusion study
The IV infusion study was performed to determine the pharmacoki-
netic parameter t1/2 of the API which was calculated to be 1.1 (±0.4) h.
Additionally, the IV infusion study resulted in a mean (±SD) AUC for
the intravenously dosed API (AUCIV) of 426 (±135) h × ng/ml.
3.2. Plasma concentration-time profiles
Fig. 2 shows the plasma concentration-time profiles up to 28 days
after IM injection of the six formulations and Fig. 3 depicts these profiles
up to 5 h after administration. For all formulations, with the exception
of F4, the mean plasma concentrations presented are based on the
observed plasma concentrations of four animal subjects. For F4 the
mean plasma concentrations presented are based on the observed plas-
ma concentrations of three animal subjects. The plasma concentrations
of the fourth subject at 511 and 679 h post dosing were considered as
outliers (as verified by the statistical criterion of Dean and Dixon).
Fig. 1 of the Supplementary information shows the individual plasma
concentration-time profiles for the four test subjects (dog 1–dog 4) of
F4. These profiles suggest an initial underperforming of F4 in dog 4, il-
lustrated by lower plasma concentrations compared to dogs 1, 2 and
3. However, at 511 h post administration a change in exposure is ob-
served which might be attributed to dose dumping and reflects on the
plasma concentration observed 679 h post dosing. As F4 behaves differ-
ently in dog 4, the results for this test subject were not used to calculate
mean plasma concentrations.
Between 0.5 and 5 h post administration the microsuspension F6
and the binary, PLGA-based formulations (F4 and F5) demonstrate
more rapidly decreasing plasma concentration-time profiles (Fig. 3)
which are in contrast to the more constant profiles of the PLGA/PVP
based matrices (F1–F3). From approximately two days (55 h) after in-
jection until the end of the study (28 days) the PLGA/PVP based matri-
ces (F1–F3) show similar plasma concentration-time profiles where F2
demonstrated the highest average plasma concentrations followed by
F1 and F3 (Fig. 2). Sample F2 shows the highest average plasma concen-
tration from three days after administration (79 h) until the end of the
study.
Table 2 represents the observed time after administration when
maximum plasma concentrations were reached (tmax,obs) for each
of the formulations. The binary formulations (F4 and F5) and the
microsuspension (F6) have a mean tmax,obs of 0.5 h, whereas for the ter-
nary formulations F1, F2 and F3 the average tmax,obs is 2.0, 3.0 and 1.5 h
respectively. However, for these ternary formulations the tmax,obs for theFig. 2. Plasma concentration-time profiles up to 28 days after IM administration of the six
formulations F1–F6 (mean ± SD, n = 4).individual test subjects varied between 0.5 and 4 h, in contrast to F4–F6
where for all test subjects a tmax,obs of 0.5 h was observed. Due to the
large standard deviation differences between tmax,obs were not statisti-
cally significant.
3.3. Bioavailability
For each formulation the observed plasma concentrationswere used
to calculate the bioavailability by Eq. (3). The results are shown in Fig. 4
where the bioavailability values, based upon the observed plasma con-
centrations until 28 days after administration (calculated based on
AUC0–∞), are depicted. For all formulations the bioavailability is consid-
ered as a measure for the amount of drug released, assuming linear
elimination kinetics. After IV administration, very rapid elimination of
the drug was observed, as reflected by the t1/2 value, obtained by the
IV infusion study, of 1.1 h ± 0.4 h. This suggests that declining plasma
concentrations observed during terminal “elimination phases” for IM
administered formulations are very likely limited by the (much slower)
absorption rates (flip-flop kinetics).
The amount of drug released from the various formulations was
evaluated by comparing the bioavailability (Fig. 4). F2 showed the
highest average bioavailability and therefore drug release, followed by
the microsuspension F6 with a mean bioavailability for F2 of 101% and
of 81% for F6 (Fig. 4). The other two ternary PLGA/PVP-based formula-
tions, F1 and F3, released API resulting in an average bioavailability of
72% and 59% respectively. The bioavailability for both F2 and F6was sig-
nificantly higher compared to that for the binary formulations of F4 and
F5. These PLGA-based formulations had the lowest total drug release
with average bioavailability values of 35% and 34% (Fig. 4).
3.4. Burst release
Burst release was identified based on the plasma concentrations ob-
tainedwithin 4 h after administration. This timepointwas selected as at
this time all plasma concentrations had reached their maximum.Table 2
Pharmacokinetic parameter tmax,obs (mean ± SD, n = 4).
Formulation tmax,obs (h)
F1 2.0 ± 1.2
F2 3.0 ± 1.0
F3 1.5 ± 1.5
F4 0.5 ± 0
F5 0.5 ± 0
F6 0.5 ± 0
Fig. 4. Bioavailability 28 days after IM administration of the six formulations F1–F6 based
on total plasma exposure of the API (AUC0–∞) (mean ± SD, n = 4).
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lease compared to the other formulationswhich is illustrated in Fig. 3 by
higher plasma concentrations already 30 min after IM injection. For
each formulation, the observed initial burst release was calculated by
Eq. (4) and the results are shown in Fig. 5. The obtained values represent
the percentage of drug released, during the first four hours post injec-
tion, of the total amount of drug released by the formulation (as a mea-
sure for burst release). The average initial burst release of F6 represents
15% of the total amount of drug released, whilst for F4 this is 13%. The
average burst release for F1, F2, F3 and F5 is 4% of the total amount of
drug released. Hence, the burst release of F6 is on average almost four
times higher compared to that of F1, F2, F3 and F5. The burst release
of F4 is on average three times higher compared to F1, F2, F3 and F5.3.5. Mimicking suspension and injection
To investigate the effect of the suspension of the powders of F1–F5 in
anaqueousmediumand subsequent IM injection this processwasmim-
icked in vitro. F1 was selected as a representative for the PLGA/PVP
based formulations (F1–F3) whereas F4 was chosen as an example for
the PLGA based formulations (F4–F5). SEM images illustrate that before
injection and exposure to an aqueous environment both formulations
consist of microspheres with a comparable, spherical morphology and
a smooth intact surface (Fig. 6A and B). The friction caused by forcing
the suspension through the needle did not result in rupture of the
shell structured microspheres. However, after exposure to an aqueous
environment (the suspension medium) the microspheres of both
model formulations show a distinct morphology. The particles of F4Fig. 5. Initial burst release 4 h post administration of the six formulations, expressed as the
percentage of drug released (mean ± SD, n = 4).are still spherical with an intact and smooth surface whereas the parti-
cles of formulation F1 have a more irregular shape (Fig. 6C and D).
4. Discussion
The six model formulations F1–F6 (Table 1) represent the three dif-
ferent solubility enhancing strategies selected. F1–F3 exemplify the first
strategy, being solid dispersions of the poorly soluble API in a PLGA/
PVP-based matrix. A comparison of F1 and F2 demonstrated the influ-
ence of an increase in the amount of PLGA (from 25 to 45 wt.%). Addi-
tionally, F3 was developed to assess the influence of the molecular
weight of PVP used. F4 and F5 represent the second formulation strategy
which is the solid dispersion of the PI in a pure PLGA matrix. Here, the
influence of the manufacturing method was assessed by comparing a
spray-dried formulation (F4) to a formulation prepared by the emulsion
method (F5). F6 is a representative of the third formulation strategy se-
lected, being particle size reduction.
The six formulations F1–F6 (Table 1), representing the three differ-
ent formulation strategies, have previously been physicochemically
characterized [19]. Physicochemical characterization of these model
formulations showed that all ternary formulations (F1–F3) existed as
a PLGA-rich surface layer containing small amounts of PVP and an un-
derlying PVP-rich phase containing small amounts of PLGA. The API
was molecularly dispersed in the polymeric matrix. Additionally for
F3, a separate amorphous drug phasewas detected. The binary formula-
tions, F4 and F5, contained a molecular dispersion of the drug as well.
Furthermore F5 contained a crystalline drug fraction and had a higher
drug surface coverage. F5 had a larger particle size, with a d50 value of
5.62 μm, compared to the d50 value of the other formulations which
was averagely 2.99 μm. Moreover, the higher surface area of F5 com-
pared to F1–F4 indicates that particles of F5 aremore porous. The differ-
ent manufacturingmethod of F5 compared to F1–F4 (emulsionmethod
compared to spray drying) is held responsible for these observed differ-
ences in particle characteristics. The polymeric formulations, F1–F5, are
schematically represented in Fig. 7. The microsuspension F6 existed of
both crystalline and amorphous API. In summary, the six formulations
differed in composition as well as structural and physicochemical char-
acteristics [19]. In the current study the in vivoperformance of these for-
mulations was evaluated in male Beagle dogs.
4.1. Solid dispersions in a water-insoluble PLGA matrix (F4–F5)
The development of microspheres based on PLGA is one of the most
successful applications of long-acting injectables. The reasons for this
success are the biocompatibility and biodegradability of the polymer,
the fact that PLGA has been approved by the FDA for parenteral use
and its suitability to tailor sustained drug release by varying the proper-
ties of the polymer. Multiple studies already contributed to insights in
the in vitro and in vivo performance of this type of formulations and
identified critical attributes to the processes involved [20–30].
The two binary PLGA-based formulations evaluated in this study dif-
fered in that the spray-dried formulation (F4) showed a significant ini-
tial burst release in vivo, in contrast to the formulation prepared by the
emulsion method (F5) (Figs. 3 and 5). This burst release was not only
significantly higher compared to the burst release observed for F5, but
also compared to the burst observed for the ternary formulations F1–
F3. Subsequently this burst was followed by a fast decline in plasma
concentration (Fig. 3). This initial burst for F4 represented 13% of the
total amount of drug released, in contrast to F5, for which the burst re-
lease accounted for 5% of the total amount of drug released. This implies
that for F5 the drug is more gradually released compared to F4 and
therefore F5 is more suitable for sustained release.
The difference in manufacturingmethods between both formulations
did not have a significant influence upon their observed mean bioavail-
ability (35% and 34%) and hence the total amount of drug released
(Fig. 4). Both binary formulations showed a lower average bioavailability
Fig. 6. SEM images. whereA=F1before exposure to a releasemedium, B=F1 before exposure to a releasemedium, C=F1 after exposure to a releasemedium, D=F4 after exposure to a
release medium. F1 was selected as a representative for the PLGA/PVP-based formulations whereas F4 was chosen as an example for the PLGA-based formulations.
6 J. Meeus et al. / Journal of Controlled Release 199 (2015) 1–9compared to the ternary formulations (Fig. 4) indicating the advantage of
inclusion of PVP in terms of the extent of drug released from these
formulations.
The early tmax,obs (0.5 h, Table 2) combined with the fast decrease in
plasma concentration-time profiles for formulations F4 and F5 suggest
that they are less suitable for long-term release compared to the ternary
formulations, for which a more constant and prolonged release is ob-
served (Figs. 2–3). These observations suggest a benefit of inclusion of
PVP in the polymeric matrix to obtain a more sustained release.
It is noteworthy that in oneof the four test subjects of F4 threeweeks
after administration a late burst releasewas observed. This late burst re-
sulted in a total amount of 88% of drug released compared to an average
value of 35% for the three other test subjects. This high drug release
might be attributed to sudden erosion of the PLGA matrix and conse-
quently disintegration of the microspheres. This divergence in velocity
of the erosion of the PLGA matrix and the consequent differences in
the observed release profile between the different test subjects is a po-
tential drawback of this formulation strategy.
4.2. Solid dispersions in a biphasic matrix consisting of water-insoluble
PLGA and water-soluble PVP (F1–F3)
Fig. 3 demonstrates the more constant and prolonged plasma
concentration-time profiles (0.5–5 h after injection) of the PLGA/PVP-
based matrices compared to the other formulations. Additionally theFig. 7. Schematic representation of the polymeric formulations F1–F5. PLGA in green, PVP in re
reader is referred to the web version of this article.)generally higher plasma concentrations observed one to two weeks
after IM injection (Fig. 2) suggest that these PLGA/PVP matrices are
more suitable for sustained release. The higher mean bioavailability of
these ternary formulations compared to the binary formulations indi-
cates a higher drug release (Fig. 4). Formulation F2 showed the highest
bioavailability (101%) suggesting that essentially all drugs present in
this formulation is released.
Overall, when the binary PLGA-based formulations were compared
to the ternary PLGA/PVP-based formulations it can be concluded that
the addition of PVPwas beneficial for both the amount of drug released
and sustained drug release. This can be explained by the structure of the
PLGA/PVP-based matrices which are known to consist of a PLGA-rich
surface layer containing small amounts of PVP and an underlying PVP-
rich phase containing small amounts of PLGA [12,13]. The releasemech-
anism is therefore dominated by fast dissolution of the small domains of
PVP present in the PLGA layer due to the high solubility of PVP. The
resulting pores in the PLGA surface layer allow ingression of aqueous
fluids into the particles, followed by fast dissolution of the molecularly
dispersed API and diffusion out of the microspheres. Hence, the pres-
ence of PVP in the PLGAmatrix results in a higher extent of drug release
as the resulting pores allow water ingression deeper into the particle
compared to into a bulk eroding PLGA matrix. Consequently an in-
creased surface area is exposed to the release mediumwith an increase
in drug dissolution and resulting drug release (Fig. 8A). Additionally, the
hydrophilic nature of PVP will favour water ingression into the pored and API in yellow. (For interpretation of the references to color in this figure legend, the
Fig. 8. The structural evolution of a PLGA/PVP-based matrix and a PLGA-based matrix when exposed to a release environment, where A = short-term exposure and B = long-term
exposure. PLGA in green, PVP in red and API in yellow. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this article.)
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Similarly PVP contributes to the long-term release of these formulations
as the pore network originating from dissolved PVP expands deeper
into the particles with longer exposure to the aqueous environment.
This results in increased access to the API dispersed in the polymeric
matrix with depth from the surface which acts as a reservoir (Fig. 8B).
It could be concluded that the pore network originating from dissolved
PVP controls the observed drug release. A schematic representation is
hypothesized in Fig. 8 where the structural evolution of a PLGA/PVP-
based matrix when exposed to a release environment is compared to
that of a PLGA-based matrix. The difference in structural evolution of a
PLGA/PVP-based matrix compared to a PLGA-based matrix when ex-
posed to an aqueous milieu is demonstrated by the SEM images in
Fig. 6. Sample F1 was selected as being representative of the PLGA/
PVP-based formulations whereas F4 was chosen as an example for the
PLGA-based formulations. It is clear that after exposure to an aqueous
environment the microspheres of both model formulations show a dis-
tinct morphology. The particles of F4 are still spherical with an intact
and smooth surface whereas the particles of F1 have a more irregular
shape due to the dissolved PVP. This induces increased access and in-
gression of water into these particles via the resulting pores. This poros-
ity enables the exposure of an increased surface area with consequently
an increase in drug dissolution and drug release.
Matrix porosity of a drug delivery systemhas already been identified
as a parameter able to influence its release profile and has already been
manipulated to do so [25]. Porosity can be influenced by selection of an
adequate manufacturing method (often via a w/o/w emulsion method
[25,31]) or by inclusion of pore forming agents (e.g. NaCl crystals [32]
or HPC [33]). In our PLGA/PVP-based microspheres PVP acts as a pore
forming agent but it has the additional capacity to improve both water
ingression into the particles (by its hydrophilicity) and, of great impor-
tance, the solubility of the API.
From the three ternary formulations F3 appears the least suitable for
sustained release, as suggested by its plasma concentration-time profile
(Fig. 2) combined with its lower average tmax,obs compared to F1 and F2
(Table 2). Additionally a lack of detectable plasma concentrations after
three weeks (511 h) indicates that there was no longer significantdrug release (Fig. 2). From the three PLGA/PVP-based formulations F3
exhibits the lowest bioavailability (Fig. 4). These observations indicate
an influence of themolecularweight of the PVP used as this formulation
only differs from F2 by the molecular weight of PVP (PVP K12 vs PVP
K30). Hence the use of PVP with a lower molecular weight results in
less prolonged drug release as well as a lower amount of drug released.
This would potentially allow tailoring of the desired release profile by
changing the molecular weight of the PVP used.
A comparison of the plasma concentration-time profiles of F1 and F2
indicates that F2 results in higher average plasma concentrations by the
end of the study (Fig. 2). Additionally its higher mean tmax,obs suggests
that an increase in the amount of PLGA from 25 to 45 wt.% results in a
more sustained release (Table 2). This is not surprising as previous stud-
ies have demonstrated that the thickness of the PLGA surface layer in-
creased with a raise in the amount of PLGA in the microspheres [12].
As PLGA is water insoluble it is expected that the thickness of this
PLGA surface layer has an influence upon drug release kinetics where
the thicker the PLGA layer, the more prolonged the observed release.
The prolonging influence of PLGA on the release could be furthered by
increasing the amount of PLGA present in the formulation. Comparing
the bioavailability of F1 and F2 suggests that the amount of PLGA pres-
ent in the formulations also influences the amount of drug released. This
might be attributed to the fact that changing the PLGA/PVP ratio influ-
ences the miscibility of the system. This will result in a difference in
the PVP pore network andmight consequently affect the release. All ter-
nary formulations showed a comparable initial burst (Fig. 5).
Suspension of the powders of the polymeric formulations F1–F5
with a concentration of 100 mg/ml resulted in a viscous suspension.
This impeded facile injection of these formulations. Lowering the con-
centration of the injected formulation could be one approach to facili-
tate injection of these formulations.
4.3. Particle size reduction (F6)
Particle size reduction is a known strategy to increase the dissolution
rate of a drug via an increase in surface area [1,2,16]. However, for poor-
ly soluble APIs particle size reduction will still result in a relatively low
8 J. Meeus et al. / Journal of Controlled Release 199 (2015) 1–9dissolution rate and hence sustained release [11,34,35]. Consequently,
for this type of API, particle size reduction is often used as a method to
develop a sustained release formulation whichwas the approach inves-
tigated here by means of F6.
The microsuspension showed an initial high burst release of the
API and reached maximum plasma concentrations 0.5 h after admin-
istration (Fig. 3). At 4 h post administration 15% of the total amount
drug released was already released (Fig. 5). The observed burst re-
lease was followed by a fast decline in plasma concentrations be-
tween 0.5 and 6 h after administration (Fig. 3). Sample F6 was also
the only formulation for which no detectable plasma concentrations
could be observed from two weeks (343 h) after injection onwards
(Fig. 2). These observations illustrate that of all formulations tested
this microsuspension is the least suitable for sustained release appli-
cations for this API. The faster drug release can be attributed to the
reduction in particle size, used as dissolution rate enhancing strategy
for this formulation.
Themeanbioavailability of 81% for this formulation indicates that al-
though particle size reduction increased dissolution rate, less drug was
released or reached the systemic circulation compared to F2. Therefore,
for this drug, particle size reduction was a suitable strategy to increase
dissolution rate but it was less applicable for the development of a
sustained release formulation.
For the various formulations strategies tested the PLGA/PVP-
based solid dispersion F2 is the most suitable to obtain a long-
acting pharmacokinetic (PK) profile which is illustrated by its higher
average tmax,obs (3.0 h) compared to the other formulations. Addi-
tionally this formulation results in the highest plasma concentra-
tions from three days after administration onwards until the end of
the study (28 days). Compared to the other formulations tested, F2
released the highest amount of drug for the same amount of drug
dosed, which was illustrated by its higher mean bioavailability.
This is advantageous in terms of total mass of formulation to be
suspended and therefore the volume to be administered. For (IM) in-
jectable formulations the volume injected is preferably as small as
possible to avoid pain upon injection, irritation and inflammation.
These findings designate a novel formulation concept based on the
solid dispersion of a poorly soluble API in a PLGA/PVP-based matrix
as an advisable strategy for the development of long-acting inject-
ables of poorly soluble APIs. The combination of these two polymers
was advantageous in terms of a more sustained release as well as a
higher extent of drug release. This formulation approach would es-
pecially be beneficial for formulations where a less than desirable
amount of drug is released from the water-insoluble matrix and for
formulations where sufficient diffusion out of the carrier is limited
due to a large molecular size (e.g. proteins). In both cases the PVP
pore network could facilitate diffusion of the API out of the matrix.5. Conclusions
An in vivo evaluation of different formulation strategies has demon-
strated the benefit of a novel formulation strategy, namely combining
water-soluble polymer PVP and a water-insoluble PLGA as a matrix for
solid dispersions to develop long-term release formulations. The benefit
is two-fold and comprises a more sustained release as well as a higher
extent of drug release from the polymeric matrix. This was explained
based on the structure of these PLGA/PVP-based matrices where the
pore network originating from rapidly dissolving PVP results in an in-
creasing access of the aqueous release medium to the API dispersed in
the polymericmatrix. This increased access to drug dispersed in thema-
trix with depth from the surface acts as a reservoir with a higher extent
of and more prolonged drug release as a result. The results suggest that
for the PLGA/PVP-based formulations the release profile can be tailored
by changing themolecularweight of PVP and the amount of PLGA in the
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